000277874 001__ 277874
000277874 005__ 20240229162349.0
000277874 0247_ $$2doi$$a10.3390/cancers15143672
000277874 0247_ $$2pmid$$apmid:37509333
000277874 0247_ $$2pmc$$apmc:PMC10377531
000277874 0247_ $$2altmetric$$aaltmetric:151703199
000277874 037__ $$aDKFZ-2023-01542
000277874 041__ $$aEnglish
000277874 082__ $$a610
000277874 1001_ $$00000-0003-1405-4897$$aBarbour, Andrew B$$b0
000277874 245__ $$aThe Judicious Use of Stereotactic Ablative Radiotherapy in the Primary Management of Localized Renal Cell Carcinoma.
000277874 260__ $$aBasel$$bMDPI$$c2023
000277874 3367_ $$2DRIVER$$aarticle
000277874 3367_ $$2DataCite$$aOutput Types/Journal article
000277874 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1690801931_20264$$xReview Article
000277874 3367_ $$2BibTeX$$aARTICLE
000277874 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000277874 3367_ $$00$$2EndNote$$aJournal Article
000277874 520__ $$aLocalized renal cell carcinoma is primarily managed surgically, but this disease commonly presents in highly comorbid patients who are poor operative candidates. Less invasive techniques, such as cryoablation and radiofrequency ablation, are effective, but require percutaneous or laparoscopic access, while generally being limited to cT1a tumors without proximity to the renal pelvis or ureter. Active surveillance is another management option for small renal masses, but many patients desire treatment or are poor candidates for active surveillance. For poor surgical candidates, a growing body of evidence supports stereotactic ablative radiotherapy (SABR) as a safe and effective non-invasive treatment modality. For example, a recent multi-institution individual patient data meta-analysis of 190 patients managed with SABR estimated a 5.5% five-year cumulative incidence of local failure with one patient experiencing grade 4 toxicity, and no other grade ≥3 toxic events. Here, we discuss the recent developments in SABR for the management of localized renal cell carcinoma, highlighting key concepts of appropriate patient selection, treatment design, treatment delivery, and response assessment.
000277874 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000277874 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000277874 650_7 $$2Other$$aRCC
000277874 650_7 $$2Other$$aSABR
000277874 650_7 $$2Other$$aSBRT
000277874 650_7 $$2Other$$akidney cancer
000277874 650_7 $$2Other$$aradiation oncology
000277874 650_7 $$2Other$$arenal cancer
000277874 650_7 $$2Other$$arenal carcinoma
000277874 650_7 $$2Other$$astereotactic body radiation therapy
000277874 7001_ $$0P:(DE-HGF)0$$aKirste, Simon$$b1
000277874 7001_ $$0P:(DE-HGF)0$$aGrosu, Anca-Liga$$b2
000277874 7001_ $$00000-0003-2840-0658$$aSiva, Shankar$$b3
000277874 7001_ $$aLouie, Alexander V$$b4
000277874 7001_ $$00000-0002-3512-1166$$aOnishi, Hiroshi$$b5
000277874 7001_ $$00000-0003-4013-1980$$aSwaminath, Anand$$b6
000277874 7001_ $$aTeh, Bin S$$b7
000277874 7001_ $$aPsutka, Sarah P$$b8
000277874 7001_ $$aWeg, Emily S$$b9
000277874 7001_ $$aChen, Jonathan J$$b10
000277874 7001_ $$aZeng, Jing$$b11
000277874 7001_ $$aGore, John L$$b12
000277874 7001_ $$00000-0002-0305-7745$$aHall, Evan$$b13
000277874 7001_ $$aLiao, Jay J$$b14
000277874 7001_ $$aCorrea, Rohann J M$$b15
000277874 7001_ $$aLo, Simon S$$b16
000277874 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers15143672$$gVol. 15, no. 14, p. 3672 -$$n14$$p3672$$tCancers$$v15$$x2072-6694$$y2023
000277874 909CO $$ooai:inrepo02.dkfz.de:277874$$pVDB
000277874 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000277874 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000277874 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000277874 9141_ $$y2023
000277874 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2022-01-24T07:56:58Z
000277874 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-30
000277874 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-30
000277874 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-30
000277874 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-30
000277874 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-30
000277874 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2022$$d2023-10-26
000277874 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000277874 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000277874 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000277874 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-31T16:07:06Z
000277874 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-31T16:07:06Z
000277874 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-07-31T16:07:06Z
000277874 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000277874 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000277874 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000277874 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000277874 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000277874 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2022$$d2023-10-26
000277874 9201_ $$0I:(DE-He78)FR01-20160331$$kFR01$$lDKTK Koordinierungsstelle Freiburg$$x0
000277874 980__ $$ajournal
000277874 980__ $$aVDB
000277874 980__ $$aI:(DE-He78)FR01-20160331
000277874 980__ $$aUNRESTRICTED